Treatment for Acute Lymphoblastic Leukemia (ALL)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
St. Jude Children's Research Hospital, Memphis, TN
Acute Lymphoblastic Leukemia (ALL)+3 More
Eligibility
18 - 65
All Sexes
Eligible conditions
Select

Study Summary

Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

See full description

Eligible Conditions

  • Acute Lymphoblastic Leukemia (ALL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Acute Lymphoblastic Leukemia (ALL)

Study Objectives

This trial is evaluating whether Treatment will improve 3 primary outcomes and 3 secondary outcomes in patients with Acute Lymphoblastic Leukemia (ALL). Measurement will happen over the course of Baseline and 6-month follow-up.

Baseline & 6-month follow-up
Direct Testing of Executive Function: Change in Cognitive Flexibility in baseline to 6 months
Direct Testing of Executive Function: Change in Verbal Fluency from baseline to 6 months
Direct Testing of Executive Function: Change in Working Memory from baseline to 6 months
Baseline and 6-month follow-up
Change in Brain Connectivity from baseline to 6 months
Change in Patient-Reported Symptoms of Executive Functioning from baseline to 6 months
Change in Regional Brian Activation from baseline to 6 months

Trial Safety

Safety Progress

1 of 3

Other trials for Acute Lymphoblastic Leukemia (ALL)

Trial Design

2 Treatment Groups

Active tDCS
1 of 2
Sham tDCS
1 of 2
Active Control
Non-Treatment Group

This trial requires 104 total participants across 2 different treatment groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.

Sham tDCS
Device
Remotely delivered sham tDCS + cognitive training
Active tDCS
Device
Remotely delivered active tDCS + cognitive training

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline & 6-month follow-up
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly baseline & 6-month follow-up for reporting.

Closest Location

St. Jude Children's Research Hospital - Memphis, TN

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. There are 8 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Enrolled on St. Jude Lifetime Cohort Study
Completed treatment for acute lymphoblastic leukemia (ALL) at SJCRH < 21 years at diagnosis
≥ 5 years post-diagnosis of ALL
≥ 2 years post-treatment completion deemed to impact the central nervous system.
Currently between 18 and 39 years of age
English language proficiency
Executive dysfunction defined as having an age-adjusted standard score <16th percentile on Trail Making Test Part B, Controlled Oral Word association Test, or Digit Span Backward
Patient-reported executive dysfunction defined as a standard score >84th percentile on the Childhood Cancer Survivor Study Neurocognitive Questionnaire or the Behavior Rating Scale of Executive Function

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Acute Lymphoblastic Leukemia (ALL) by sharing your contact details with the study coordinator.